MedTrace Logo

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

NCT04884906 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-05-13

No results posted yet for this study

Summary

To evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer

Conditions

  • Locally Advanced Cervical Cancer

Interventions

BIOLOGICAL

Camrelizumab

200mg/m2, iv, d1, Q3W, a total of 6 cycles

RADIATION

radiotherapy

1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.

DRUG

Albumin Paclitaxel

260mg/m2, iv, d1, Q3W, a total of 6 cycles

DRUG

Cisplatin

80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-11-01
Completion
2024-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04884906 on ClinicalTrials.gov